Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Renal Impairment
Interventions
DRUG

Elinogrel

100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)

Trial Locations (2)

37920

NOCR-Knoxville, Knoxville

55404

DaVita Clinical Research, Minneapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Portola Pharmaceuticals

INDUSTRY